参考文献/References:
[1] Al-Salameh A,Baudry C,Cohen R.Update on multiple endocrine neoplasia type 1 and 2[J].Presse Med,2018,47(9):722-731.DOI:10.1016/j.lpm.2018.03.005.
[2] 中国医师协会外科医师分会甲状腺外科医师委员会,中国抗癌协会甲状腺癌专业委员会,中国研究型医院学会甲状腺疾病专业委员会.甲状腺髓样癌诊断与治疗中国专家共识(2020版)[J].中国实用外科杂志,2020,40(9):1012-1020.DOI:10.19538/j.cjps.issn1005-2208.2020.09.03.
[3] Brauckhoff M,Machens A,Hess S,et al.Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN2B:An exploratory analysis[J].Surgery,2008,144(6):1044-1050; discussion 1050-1053.DOI:10.1016/j.surg.2008.08.028.
[4] Raue F,Dralle H,Machens A,et al.Long-Term survivorship in multiple endocrine neoplasia type 2B diagnosed before and in the new millennium[J].J Clin Endocrinol Metab,2018,103(1):235-243.DOI:10.1210/jc.2017-01884.
[5] Raue F,Kotzerke J,Reinwein D,et al.Prognostic factors in medullary thyroid carcinoma:evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register[J].Clin Investig,1993,71(1):7-12.DOI:10.1007/BF00210956.
[6] Cupisti K,Wolf A,Raffel A,et al.Long-term clinical and biochemical follow-up in medullary thyroid carcinoma:a single institution's experience over 20 years[J].Ann Surg,2007,246(5):815-821.DOI:10.1097/SLA.0b013e31813e66b9.
[7] Castinetti F,Waguespack SG,Machens A,et al.Natural history,treatment,and long-term follow up of patients with multiple endocrine neoplasia type 2B:an international,multicentre,retrospective study[J].Lancet Diabetes Endocrinol,2019,7(3):213-220.DOI:10.1016/S2213-8587(18)30336-X.
[8] Li D,Chi Y,Chen X,et al.Anlotinib in locally advanced or metastatic medullary thyroid carcinoma:a randomized,double-blind phase ⅡB trial[J].Clin Cancer Res,2021,27(13):3567-3575.DOI:10.1158/1078-0432.CCR-20-2950.
[9] 杨华,吴红花,布楠,等.寂静性嗜铬细胞瘤临床特点分析[J].中华医学杂志,2018,98(34):2727-2731.DOI:10.3760/cma.j.issn.0376-2491.2018.34.010.
[10] Wells SA Jr,Asa SL,Dralle H,et al.Revised American thyroid association guidelines for the management of medullary thyroid carcinoma[J].Thyroid,2015,25(6):567-610.DOI:10.1089/thy.2014.0335.
[11] 刘瑶,付洁,符月,等.多发性内分泌腺瘤病2B型一例[J].中华口腔医学杂志,2015,50(10):590-592.DOI:10.3760/cma.j.issn.1002-0098.2015.10.004.
[12] 赵坚强,戚晓平,李嘉根,等.多发性内分泌腺瘤2B型一例并文献复习[J].中华全科医师杂志,2015,14(3):194-199.DOI:10.3760/cma.j.issn.1671-7368.2015.03.010.
[13] 董德鑫,李汉忠.多发性内分泌腺瘤病2B型合并类马方综合征一例报告并文献复习[J].中华泌尿外科杂志,2014,35(3):161-164.DOI:10.3760/cma.j.issn.1000-6702.2014.03.001.
[14] 张翼飞,洪洁,赵咏桔,等.RET原癌基因点突变所致多发性内分泌腺瘤病2B型一例家系研究[J].中华内科杂志,2003,42(1):20-23.DOI:10.3760/j.issn:0578-1426.2003.01.006.
[15] 谢燚,李汉忠.多发性内分泌腺瘤病2B型四例报告并文献复习[J].中华泌尿外科杂志,2014,35(7):481-485.DOI:10.3760/cma.j.issn.1000-6702.2014.07.001.
[16] 茅江峰,王志新,李梅,等.RET基因突变导致的多发性内分泌腺瘤病2B型患者的临床特点及诊治经验[J].中华医学杂志,2013,93(6):445-448.DOI:10.3760/cma.j.issn.0376-2491.2013.06.013.
[17] 黄培颖,陈宁,宋海曲,等.RET原癌基因突变致多发性内分泌腺瘤病2b型临床诊治[J].中国全科医学,2016,19(2):229-232.DOI:10.3969/j.issn.1007-9572.2016.02.022.
[18] Zhang L,Guo Y,Ye L,et al.Severe constipation as the first clinical manifestation in multiple endocrine neoplasia type 2B:a case report and literature review[J].BMC Pediatr,2020,20(1):318.DOI:10.1186/s12887-020-02224-4.
[19] 周瑜琳,赵咏桔,成昌友,等.五个多发性内分泌肿瘤2B家系的临床分析和RET原癌基因突变研究[J].中华内分泌代谢杂志,2006,22(6):549-553.DOI:10.3760/j.issn:1000-6699.2006.06.012.
[20] 张永侠,张彬,刘文胜,等.行RET原癌基因检测的多发性内分泌肿瘤2B型一例[J].中华耳鼻咽喉头颈外科杂志,2014,(5):422-424.DOI:10.3760/cma.j.issn.1673-0860.2014.05.019.
[21] Xu L,Shek KW,Wong KC,et al.Megacolon as the presenting feature of multiple endocrine neoplasia type 2B:a case report[J].Hong Kong Med J,2019,25(6):483-486.DOI:10.12809/hkmj197827.
[22] Qi XP,Lin GB,Chen B,et al.Multiple endocrine neoplasia type 2B associated mixed medullary and follicular thyroid carcinoma in a Chinese patient with RET M918T germline mutation[J].Endocr Metab Immune Disord Drug Targets,2021,21(3):554-560.DOI:10.2174/1871530320666200713092633.
[23] 金萍,胡文沐,杨幼波,等.RET基因p.M918T突变导致多发性内分泌肿瘤-Ⅱb型1例[J].中南大学学报(医学版),2020,45(10):1261-1265.DOI:10.11817/j.issn.1672-7347.2020.190140.
[24] 燕东亮,李甦,曹庆伟,等.2B型多发性内分泌肿瘤家族RET基因突变检测分析[J].中华泌尿外科杂志,2003,24(1):60.DOI:10.3760/j:issn:1000-6702.2003.01.037.
[25] Zhou Y,Zhao Y,Cui B,et al.RET proto-oncogene mutations are restricted to codons 634 and 918in mainland Chinese families with MEN2A and MEN2B[J].Clin Endocrinol(Oxf),2007,67(4):570-576.DOI:10.1111/j.1365-2265.2007.02927.x.
[26] 马晓森,王芬,崔云英,等.RET突变的嗜铬细胞瘤患者的临床及基因特征[J].基础医学与临床,2020,40(12):1651-1655.DOI:10.3969/j.issn.1001-6325.2020.12.009.
[27] 顾丽群,赵咏桔,赵红燕,等.一个RET原癌基因Met918Thr突变的多发性内分泌腺瘤病Ⅱb家系报道[J].上海医学,2004,27(8):592-593.DOI:10.3969/j.issn.0253-9934.2004.08.017.
[28] Wang J,Zhang B,Liu W,et al.Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives[J].Fam Cancer,2016,15(1):99-104.DOI:10.1007/s10689-015-9828-6.
[29] 张枝桥,刘小伟,董方田.多发性内分泌腺瘤病2b型患者眼部特征分析[J].中华医学杂志,2012,92(2):119-121.DOI:10.3760/cma.j.issn.0376-2491.2012.02.012.
[30] 范治璐,鞠红卫,于洋,等.2型多发性内分泌肿瘤诊治(附2例)[J].中华内分泌外科杂志,2010,04(4):276-277.DOI:10.3760/cma.j.issn.1674-6090.2010.04.022.
[31] 燕东亮,许纯孝,张东青,等.多发性内分泌肿瘤2b型(附一例报告并文献复习)[J].中华泌尿外科杂志,2001,22(11):688-690.DOI:10.3760/j:issn:1000-6702.2001.11.015.
[32] 赵铁耘,李秀钧,沈宏.多发性内分泌腺瘤2B型1例报告[J].华西医科大学学报,2000,31(1):128.DOI:10.3969/j.issn.1672-173X.2000.01.045.
[33] 王立明,赵永福,汤洪波,等.多发性内分泌肿瘤Ⅱb型--附1例报告并文献复习[J].中国现代普通外科进展,2004,7(1):55-58.DOI:10.3969/j.issn.1009-9905.2004.01.017.
[34] 吴岚,肖璇,周永梅,等.多发性内分泌腺瘤病2B型特征性口腔黏膜表现家系[J].临床口腔医学杂志,2016,32(7):410-412.DOI:10.3969/j.issn.1003-1634.2016.07.008.
[35] 陈迪,李莹.多发性内分泌腺瘤病2B型特征性眼部表现一例[J].眼科,2014,23(1):46,56.DOI:10.13281/j.cnki.issn.1004-4469.2014.01.017.